


## Prophylactic **TRE**atment **O**f the du**C**tus **A**rteriosus in **P**reterm infants by **A**cetaminophen


Dear Investigators, dear National Hubs,

After 6 weeks of suspension of inclusions, we are delighted to announce that **regulatory approvals on protocol amendment have been obtained in 4 countries** : Belgium, Estonia, France and Switzerland. **9 sites have re-opened for recruitment since March 30, 2021.**

### Overview of the safety issue and its resolution:



### Projection of inclusions Phase III:



### Inclusions status:

Phase II : 13 inclusions / Target : 30 patients  
 Phase III : 11 inclusions / Target : 794 patients

### Recommendations to standardize Prophylactic Hydrocortisone for NICU having prophylactic hydrocortisone integrated in their standard of care:

No utilization of prophylactic hydrocortisone in case of:

- IUGR (birth weight < 10th percentile of your referent curves)
- Or documented cord blood cortisol levels > 900 nmol/L for the preterm infants hospitalized in the NICUs analyzing cortisol in the cord blood
- Or no oxygen dependency during the first 24 hours of life.

TREOCAPA is a study co-developed with parents and their European representatives.

This study is funded by the c4c project. Find out more here: <https://conect4children.org/>